Entera Bio Ltd. (5DT.F)

2,1600 +0,1000 (+4,85%) Börsenschluss: 08:01AM CEST

Entera Bio Ltd.

Kiryat Hadassah Minrav Building
Fifth Floor
Jerusalem 9112002
Israel
972 2 532 7151
https://www.enterabio.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 17

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Ms. Miranda J. Toledano M.B.A.	CEO & Director	388,22k	N/A	1977
Ms. Dana Yaacov-Garbeli CPA	Chief Financial Officer	179,25k	N/A	1983
Dr. Hillel Galitzer M.B.A., Ph.D.	Chief Operating Officer	274,91k	N/A	1978
Dr. Arthur C. Santora II, M.D., Ph.D.	Chief Medical Officer	329,71k	N/A	1951

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Corporate Governance

Entera Bio Ltd.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.